



PATENT APPLICATION

TECH CENTER 1600/2900

CHG PDP 5/2003
1043

JUN 18 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Toshikazu NAKAMURA

Appln. No.: 09/674,377

Group Art Unit: 114

Filed: October 30, 2000

Examiner: Unknown

JUN 18 2002

RECEIVED

For: NEOVASCULARIZATION INHIBITORS

PRELIMINARY AMENDMENT

RECEIVED

Commissioner for Patents
Washington, D.C. 20231

JUL 08 2002

TECH CENTER 1600/2900

Sir:

Prior to examination, please amend the above-identified application as follows:

IN THE SPECIFICATION:

Please amend the specification as follows:

Page 6, lines 10-14, delete in their entirety, and insert therefor

-- Fig. 13 indicates that HGF/NK4 has the action to inhibit the growth (A) and metastasis (B) of Jyg mammary tumor cells; A shows the time course of the volume of a transplanted tumor mass and B shows the number of metastatic foci. --.

Page 21, lines 24-25, delete in their entirety.

Page 22, lines 1-25, delete in their entirety.

Page 23, lines 1-2, delete in their entirety, and insert therefor

-- Regarding the manufacture of tablets, the carrier that can be used includes various excipients such as lactose, sucrose, sodium chloride, glucose, urea, starch, calcium carbonate.

05/31/2002 NM0HMM1 00000063 09674377

01 FC:103
02 FC:102

396.00 OP
1092.00 OP

RECEIVED

JAN 16 2003

JUL 08 2002
TECH CENTER 1600/2900

RECEIVED

TECH CENTER 1600/2900